Similar articles for PMID: 29764250

Year	Number of Results
2012	1
2013	4
2014	11
2015	18
2016	15
2017	19
2018	16
2019	17
2020	9
2021	8
2022	2
2024	0

1

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Pleyer C, Wiestner A, Sun C. Pleyer C, et al. Leuk Lymphoma. 2018 Dec;59(12):2792-2800. doi: 10.1080/10428194.2018.1457147. Epub 2018 May 15. Leuk Lymphoma. 2018. PMID: 29764250 Free PMC article. Review.

2

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, Stetler-Stevenson M, Yuan CM, Calvo KR, Braylan RC, Valdez J, Lee YS, Wong DH, Jones J, Sun C, Marti GE, Farooqui MZ, Wiestner A. Niemann CU, et al. Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9. Clin Cancer Res. 2016. PMID: 26660519 Free PMC article. Clinical Trial.

3

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Wiestner A. Wiestner A. Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123. Haematologica. 2015. PMID: 26628631 Free PMC article. Review.

4

Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Till KJ, Pettitt AR, Slupsky JR. Till KJ, et al. J Immunol. 2015 Mar 1;194(5):2439-46. doi: 10.4049/jimmunol.1402304. Epub 2015 Jan 28. J Immunol. 2015. PMID: 25632006 Free PMC article.

5

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV. Danilov AV. Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Clin Ther. 2013. PMID: 24054703 Free PMC article. Review.

6

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, Chanan-Khan AA, Parikh SA, Slager SL, Kay NE, Call TG. Shanafelt TD, et al. J Oncol Pract. 2015 May;11(3):252-8. doi: 10.1200/JOP.2014.002469. Epub 2015 Mar 24. J Oncol Pract. 2015. PMID: 25804983

7

Idelalisib, ibrutinib show benefits in CLL.

[No authors listed] [No authors listed] Cancer Discov. 2014 Apr;4(4):382. doi: 10.1158/2159-8290.CD-NB2014-025. Epub 2014 Feb 20. Cancer Discov. 2014. PMID: 24706642 No abstract available.

8

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM. Sanford DS, et al. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):385-91. doi: 10.1016/j.clml.2015.02.019. Epub 2015 Feb 19. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25817936 Free PMC article. Review.

9

Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.

Man S, Henley P. Man S, et al. Br J Haematol. 2019 Jul;186(2):220-233. doi: 10.1111/bjh.15918. Epub 2019 Apr 3. Br J Haematol. 2019. PMID: 30945268 Free article. Review.

10

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Kondo K, et al. Leukemia. 2018 Apr;32(4):960-970. doi: 10.1038/leu.2017.304. Epub 2017 Oct 3. Leukemia. 2018. PMID: 28972595 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year